# Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

> **NCT06603623** · PHASE2 · COMPLETED · sponsor: **Biohaven Therapeutics Ltd.** · enrollment: 647 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** BHV-2100
- **DRUG:** BHV-2100
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06603623
- **Lead sponsor:** Biohaven Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-10
- **Primary completion:** 2025-03-24
- **Final completion:** 2025-03-28
- **Target enrollment:** 647 (ACTUAL)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06603623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06603623, "Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06603623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*